FIBRINOGEN, T-PA, AND PAI-1 PLASMA-LEVELS IN PATIENTS WITH PULMONARY-HYPERTENSION

被引:68
作者
HUBER, K [1 ]
BECKMANN, R [1 ]
FRANK, H [1 ]
KNEUSSL, M [1 ]
MLCZOCH, J [1 ]
BINDER, BR [1 ]
机构
[1] UNIV VIENNA, DEPT INTERNAL MED 2, DIV CARDIOL, A-1090 VIENNA, AUSTRIA
关键词
D O I
10.1164/ajrccm.150.4.7921465
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
We measured fibrinogen levels as well as the fibrinolytic parameters tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAl-1) in plasma samples obtained at basal conditions and after stimulating the fibrinolytic system by venous occlusion (VO). Samples were taken from patients with primary pulmonary hypertension (PPH), with secondary thromboembolic pulmonary hypertension (SPHTH), with secondary pulmonary hypertension due to congenital heart disease with Eisenmenger's reaction (SPHCD), and from healthy control individuals (CON). Fibrinogen levels were not significantly different between the groups with PPH and SPHTH or between SPHCD and CON. The latter groups, however, exhibited significantly lower fibrinogen plasma levels compared with PPH or SPHTH (p < 0.01). Basal plasma levels of t-PA antigen, t-PA activity, and PAl-1 activity, respectively, did not differ significantly between the study groups. After VO, mean t-PA activity levels increased to a higher extent in control subjects compared with patients with PPH, or SPHTH, or SPHCD, with significant differences only between CON and SPHTH or CON and PPH (p < 0.03). Patients with PPH and SPHTH exhibit both increased fibrinogen plasma levels and a diminished fibrinolytic response compared with healthy subjects. Moreover, the fibrinogen plasma levels in patients with SPHCD are in normal range, and the fibrinolytic response is similar to CON compared with PPH and SPHTH, thus indicating the existence of a comparable prothrombotic situation in patients with PPH and SPHTH.
引用
收藏
页码:929 / 933
页数:5
相关论文
共 35 条
[1]   FIBRINOLYTIC-ACTIVITY IN HEALTHY-VOLUNTEERS BEFORE AND AFTER 5 TO 20 MINUTES OF VENOUS OCCLUSION [J].
BAUER, J ;
BACHMANN, F .
THROMBOSIS RESEARCH, 1984, 34 (02) :159-174
[2]   PRIMARY PULMONARY-HYPERTENSION - A HISTOPATHOLOGIC STUDY OF 80 CASES [J].
BJORNSSON, J ;
EDWARDS, WD .
MAYO CLINIC PROCEEDINGS, 1985, 60 (01) :16-25
[3]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[4]   CARDIOVASCULAR RISK-FACTORS - INTERACTIVE EFFECTS OF LIPIDS, COAGULATION AND FIBRINOLYSIS [J].
DAAE, LNW ;
KIERULF, P ;
LANDAAS, S ;
URDAL, P .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1993, 53 :19-27
[5]   FIBRINOGEN - ITS ROLE IN THE HEMOSTATIC REGULATION IN ATHEROSCLEROSIS [J].
EBER, B ;
SCHUMACHER, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (02) :104-107
[6]   CLINICAL PRIMARY PULMONARY-HYPERTENSION - 3 PATHOLOGIC TYPES [J].
EDWARDS, WD ;
EDWARDS, JE .
CIRCULATION, 1977, 56 (05) :884-888
[7]   FIBRINOPEPTIDE-A - A MARKER OF ACUTE CORONARY THROMBOSIS [J].
EISENBERG, PR ;
SHERMAN, LA ;
SCHECTMAN, K ;
PEREZ, J ;
SOBEL, BE ;
JAFFE, AS .
CIRCULATION, 1985, 71 (05) :912-918
[8]   FIBRINOPEPTIDE-A LEVELS INDICATIVE OF PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION [J].
EISENBERG, PR ;
LUCORE, C ;
KAUFMAN, L ;
SOBEL, BE ;
JAFFE, AS ;
RICH, S .
CIRCULATION, 1990, 82 (03) :841-847
[9]   PRIMARY PULMONARY-HYPERTENSION [J].
FISHMAN, AP ;
PIETRA, GG .
ANNUAL REVIEW OF MEDICINE, 1980, 31 :421-431
[10]  
FRANZ RC, 1979, S AFR MED J, V55, P170